Particle News: Latest Vertex Pharmaceuticals news

FDA Approves Journavx, First Non-Opioid Painkiller in Over 20 Years

Vertex Pain Drug Fails to Outperform Placebo in Key Study, Raising Concerns

NHS Approves Groundbreaking Gene-Editing Therapy for Beta Thalassemia

NHS England Secures Long-Term Access to Cystic Fibrosis Drugs

Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Expand Kidney Disease Treatment Portfolio

Vertex's New Non-Opioid Painkiller VX-548 Shows Promise, But Raises Concerns

FDA Approves Vertex/CRISPR Gene Therapy for Beta Thalassemia

Vertex's Non-Opioid Painkiller Shows Promising Results in Mid-Stage Trial

FDA Approves New Gene Therapies for Sickle Cell Disease Amid Access Concerns

FDA Approves First Gene Therapies for Sickle Cell Anemia

FDA Approves First-Ever CRISPR Gene-Editing Treatment for Sickle Cell Disease

UK Approves World's First CRISPR-Based Treatment for Blood Disorders

Vertex Pharmaceuticals Misses Sales Estimates; UK May Discontinue Use of Its Costly Cystic Fibrosis Treatments

FDA Expected to Approve Groundbreaking CRISPR Gene-Editing Treatment for Sickle Cell Disease by December 8

FDA Closer to Approving CRISPR Gene Editing Treatment for Sickle Cell Disease

FDA to Review Potential Sickle Cell Disease Cure Based on CRISPR Gene Therapy